vTv Therapeutics (NASDAQ:VTVT) Rating Lowered to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen downgraded vTv Therapeutics from “Buy” to “Sell,” despite the broader analyst consensus remaining “Moderate Buy,” with six Buy, one Hold and one Sell rating.
• Analysts’ consensus price target is $55.83, while shares opened at $35.37 and have traded between $14.00 and $44.00 over the past year.
• vTv Therapeutics reported quarterly EPS of negative $1.05, missing the consensus estimate of negative $0.97; analysts expect a full-year loss of $2.19 per share.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "buy" rating to a "sell" rating in a research report issued on Saturday.

Other research analysts have also issued reports about the stock. HC Wainwright decreased their price target on shares of vTv Therapeutics from $45.00 to $42.00 and set a "buy" rating for the company in a research note on Thursday. Weiss Ratings raised shares of vTv Therapeutics from a "sell (d-)" rating to a "sell (d+)" rating in a research note on Monday, May 18th. Rodman & Renshaw started coverage on shares of vTv Therapeutics in a report on Tuesday, June 30th. They issued a "buy" rating and a $67.00 price objective on the stock. BTIG Research lifted their target price on shares of vTv Therapeutics from $49.00 to $57.00 and gave the company a "buy" rating in a report on Thursday, July 16th. Finally, Zacks Research cut vTv Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Thursday, June 11th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, vTv Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $55.83.

vTv Therapeutics Stock Up 2.2%

Shares of VTVT stock opened at $35.37 on Friday. The stock has a market cap of $139.36 million, a price-to-earnings ratio of -33.37 and a beta of 0.28. The business's fifty day moving average is $33.40 and its 200 day moving average is $34.80. vTv Therapeutics has a twelve month low of $14.00 and a twelve month high of $44.00.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.08). Equities research analysts expect that vTv Therapeutics will post -2.19 earnings per share for the current fiscal year.

Institutional Trading of vTv Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. purchased a new position in shares of vTv Therapeutics during the fourth quarter valued at approximately $221,000. 683 Capital Management LLC bought a new stake in vTv Therapeutics in the 4th quarter worth approximately $731,000. Finally, Geode Capital Management LLC grew its position in vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company's stock worth $1,128,000 after purchasing an additional 12,896 shares during the period. Hedge funds and other institutional investors own 17.51% of the company's stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company's lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source